About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Driver

whats all that crap ph has posted is it anything to do with erx ??

smiler
I dont read his stuff properly not.

Say No MORE !!

Nothing new just looks good.

Biotechnology Ireland
http://www.biotechinfo.ie/pooled/articles/BF_NEWSART/view.asp?Q=BF_NEWSART_216242

EXPECT NEWS THIS WEEK.. TODAY OR TOMORROW BY MY RECKONING

Article Preview
Researchers' data from the United Kingdom, Germany and United States advance cancer treatment research

Vaccine Weekly - Sep. 13, 2006
2006 SEP 13 - (NewsRx.com) -- Data on cancer treatment are outlined in reports from the United Kingdom, Germany and United States.

Study 1: A new anticancer glycolipid monoclonal antibody, SC104, directly induces tumor cell apoptosis.

According to recent research from England, "A novel monoclonal antibody was raised by immunization of mice with colorectal tumor cell lines. The fusion was screened by immunohistochemistry for binding to primary colorectal tumors. Subsequent analysis on primary disaggregated colorectal tumors show that the antibody recognizes a cell surface antigen expressed by the majority of colorectal tumors."

"Antigen characterization has shown that the antibody ...

http://www.therapeuticsdaily.com/news/article.cfm?contentValue=1078531&contentType=sentryarticle&channelID=28


EIRX THERAPEUTICS PLC ("EIRX")

POTENTIAL NEW THERAPIES FOR COLORECTAL & OTHER CANCERS


Cork, Ireland, 10th January, 2006 EiRx Therapeutics plc (AIM: ERX), the drug discovery company developing targeted therapies for cancer, is pleased to announce the filing of patent applications describing a novel class of drug candidates with potential value as treatments for a range of cancers including colorectal and breast tumours. This class of molecule is structurally dissimilar to the class of molecules for which patent applications were made in August 2005, thus ensuring a deeper pipeline of development for the treatment of colorectal and breast cancer.

Exploiting the insight afforded to them through their ALIBITM genomics platform, EiRx scientists developed EnPADTM technology to target APC-b-catenin signalling, a cellular control pathway known to play a major role in the majority of cases of colorectal cancer, as well as in several other tumour types. A custom-designed EnPADTM cell line was used to screen a focused library of drug-like, kinase inhibitor compounds, resulting in the discovery of a series of related compounds with selective activity against transformed cell types including colorectal and breast cancer cell lines. The EnPADTM technology development programme was funded in part by the Marie Curie Transfer Of Knowledge grant.

Commenting on the discovery, EiRxs Chief Scientific Officer Prof Tom Cotter said: The company's EnPADTM technology has again proven its ability to identify novel classes of molecules with selective biological activity. The class of molecules filed in the current patent applications are structurally quite different to those that were the subject of the earlier patent applications in August 2005. As a result we are in the enviable position of moving two chemical scaffolds through preclinical with the potential to treat these socio-economically important diseases.

EiRx Chairman John Pool said: Not only does filing a second class of molecule with activity against colorectal and breast cancer endorse our EnPADTM approach in drug discovery; it also demonstrates that EiRx has set its sights firmly on the identification and development of novel molecules to treat cancer. Having two series of molecules in preclinical development, both with the potential to treat colorectal and breast cancer, demonstrates that EiRx has the potential to rapidly become a key player in these very considerable therapeutic markets.

Someone has just sold 40 million shares.

it was a broker to broker you numbskull, news coming..

40mil buy just gone through now

Laurie
Take no notice of PH thats his way, no sells today again and a broker to broker just as PH (news international) says.

Driver

Glad to see I did not miss much ! I must say glad I did not get any HML at 4.50 I almost got some, I think I will stick with ERX ! : )

smiler
Yep HML looks a dead duck at the moment may be a lesson to learn for the future with ERX if we have a massive sp rise, or when that is.

Driver

TO True, we live and learn, my big loss this year so far is Aisa Energy still suspended !! lets hope we all can make a few quid on erx : )

Doctors hail lung cancer breakthrough




28 September 2006
An experimental drug that extends the lives of lung cancer patients by a third has impressed doctors, who say that it is one of the first signs of progress against the disease.

Lung cancer is among the most lethal of all cancers and claims more lives each year than any other. Only five per cent of patients survive more than five years.

Efforts to find an effective treatment have failed and unlike other cancers, such as breast cancer, the death rate has not changed for more than a decade. A trial of the as yet unnamed drug, known as AS1404, in 70 patients with non-small cell lung cancer (NSCLC), the commonest kind, found they lived for 14 months on average compared with 8.8 months for those given chemotherapy alone.

Although the extra five months gained is small in absolute terms, it is a significant improvement, suggesting a genuine benefit from the drug. More than 26,000 people in Britain die from NSCLC each year.

The drug, discovered by researchers in New Zealand and developed by the UK biotechnology company, Antisoma, with backing from Cancer Research UK, is one of a new class of compounds called vascular disrupting agents. These work by destroying blood vessels that supply solid tumours on which the tumours depend to survive and grow.

The success of the phase II study lays the ground for a larger phase III trial, the outcome of which will determine whether the drug is licensed as safe and effective. AS1404 has already been shown to be effective in phase II trials of prostate and ovarian cancer.

Mark McKeage of the University of Auckland, one of the researchers, said: "It is great to see this large survival benefit with AS1404 in lung cancer patients. This makes me feel very optimistic as we progress into phase III testing."

Professor Alex Markham, chief executive of Cancer Research UK, said: "Our drug development team played an integral role in the early development of the drug and we're delighted with this news. We look forward to seeing how the drug performs in a much larger number of patients."

The charity has set up a company to raise the number of undeveloped new treatments by putting them into clinical trials. Since 1982, more than 100 agents have been put into trials.

"Over the next five years we plan to double our activity and speed up the drug development process, getting even more new drugs into clinical trials," Professor Markham said.

* Living near heavy industry may raise the risk of lung cancer. A study of women in Teesside, who lived within three miles of a chemical production complex at Billingham for at least 25 years, found they were twice as likely to develop the disease than others, after smoking and other factors were taken into account.
http://www.belfasttelegraph.co.uk/lifestyle/health_beauty/story.jsp?story=708067

Sonus Pharmaceuticals Initiates Phase 1 Clinical Trial for ...
Genetic Engineering News (press release), NY - 1 hour ago
... "This promising compound may have the ... lead oncology product candidate, TOCOSOL Paclitaxel, is currently in a Phase 3 pivotal trial in metastatic breast cancer. ...

Biothera Completes Second Phase I Clinical Trial for Cancer Drug
PipelineReview.com (press release), Spain - 6 hours ago
... I clinical trial for Imprime PGG its lead compound for activating ... and increases in survival in multiple types of cancer, including breast, lung and ...

All buys again today you can buy online at 28 so all buys.

Correction one sell at 25

so they knock it down.. rediculous

That was a short post PH

must be news tomorrow then ;-)

PH
You have worn yourself out go and have a rest.